Assess whether RWE can replace or only supplement an RCT (d5f4c8)

Situation

RWE can replace or sits with clinical-development physician because an AdCom briefing document that overstates subgroup findings hit an RWE group proposing a post-marketing study instead of a new RCT. Evidence is complete-response-letter deficiency list; write the Pharma & Life Sciences CMC and Development Pathways option that extract can carry.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Complete-response-letter deficiency list reads as RWE can replace once an AdCom briefing document that overstates subgroup findings is lined up to the same Pharma & Life Sciences population.
• Complete-response-letter deficiency list is closer to Only supplement an RCT after an AdCom briefing document that overstates subgroup findings; RWE can replace would over-claim this CMC and Development Pathways extract.
• A dual reading is still live in complete-response-letter deficiency list for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.
• Complete-response-letter deficiency list is missing the fact clinical-development physician needs after an AdCom briefing document that overstates subgroup findings; stop this Pharma & Life Sciences close.

Analysis required

• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read complete-response-letter deficiency list against an AdCom briefing document that overstates subgroup findings and write the one fact that would move RWE can replace or for clinical-development physician.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / CMC and Development Pathways packet (complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings). The follow-on CMC and Development Pathways action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.